australia
australia · page 2
- Medical
Could Australia Be the Next Country to Impose Tariffs on Canadian Cannabis?
Australia’s medical cannabis market is thriving, with revenues expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028, according to Prohibition Partners’ Global Cannabis Report: 5th Edition.
- Uncategorized
EU Moves to Improve Conditions for Embattled Biotech Sector, Ananda’s Clinical Development Pushes On, & Celadon Remains on the Brink
In response to this growing exodus of promising biotech firms, the European Union has proposed a new Biotech Act, as part of ongoing efforts by the European Commission to strengthen the continent’s biotechnology and biomanufacturing sectors, which have struggled with fragmented rules and sluggish approval processes.
- Markets & Stocks
Ananda Gets Ethics Approval for Australian Clinical Study, Synbiotic Launches Germany’s First THC-Pastille, & More from Stenocare
UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.
- Data & Analysis
Australia’s Medical Cannabis Market Set to Outgrow Europe’s Biggest Players
According to Prohibition Partners’ new Global Cannabis Report: 5th Edition, launching today, Australia’s medical cannabis revenues are expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028.
- Data & Analysis
Cannabis Down Under: Australia and New Zealand’s Regulatory Overhauls Aim to Boost Global Cannabis Presence
Australia and New Zealand are undergoing contrasting reforms in their medical cannabis regulations.
- Markets & Stocks
Jazz Pharma’s Epidiolex Approved in Canada, Apollon Nears Take Over Deal, & Stenocare Expands in Australia
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to be prescribed for a number of conditions in Canada.
- Companies
Incannex To Relocate To US From Australia And List Shares On NASDAQ
Incannex has announced it will be relocating to Delaware, United States from Australia.
- Companies
Canada’s biggest cannabis underdog SNDL delivers transformational year, & Australia’s medical cannabis sales could soon outpace Canada
Canada’s biggest cannabis underdog SNDL delivers transformational year Cannabis company and liquor retailer, SNDL Inc., had a record net revenue of $240.4 million in Q4 – 4% higher than in the previous quarter and more than 10x its Q4 2021 sales, reports Fintel.
- Press releases
Stenocare Enters Its 4th Market Starting Sales In Australia In Q4 2022
AFTER securing market access and approvals in both Denmark, Sweden and UK, STENOCARE A/S (“Stenocare”) now takes a first and firm footstep into the southern hemisphere entering Australia.
- Uncategorized
What Australian Good Manufacturing Practices certification means for Canadian cannabis
BofC Live is the daily news and interview program of Business of Cannabis.
